Seelos Therapeutics Inc (Nasdaq:SEEL) received a grant from the Team Sanfilippo Foundation to help fund open-label studies of SLS-005, its treatment for the rare neurodegenerative disorder.
The funding will go toward a Phase 2b/3 study will evaluate patients with Sanfilippo syndrome types A and B.
A portion of the grant will also be used for a seperate expanded access study for patients with types C and D as well as patients with types A and B who did not qualify for the original study.
READ: Seelos Therapeutics earns patent approval for its neuromuscular disease drug
“TSF is proud to be able to provide funding towards Seelos' Sanfilippo trial and excited to continue working with their team," TSF President Kathy Buckley said. "Improving the lives of the children and families living with Sanfilippo syndrome continues to be our main focus. We will continue to work aggressively to raise additional funds to accommodate as many children as possible into the expanded access program."
The Team Sanfilippo Foundation is a nonprofit research foundation that funds clinical trials of potential therapies.
Seelos Therapeutics is a clinical-stage biopharmaceutical company based in New York developing therapeutics for patients with central nervous system and other rare disorders.
The company’s share price climbed 4.5% to $2.11 on Monday.
—This story was updated to clarify that there are two separate studies, rather than a single encompassing one—
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel
